Cargando…

Interleukin 17 enhances bone morphogenetic protein-2-induced ectopic bone formation

Interleukin 17 (IL-17) stimulates the osteogenic differentiation of progenitor cells in vitro through a synergy with bone morphogenetic protein (BMP)-2. This study investigates whether the diverse responses mediated by IL-17 in vivo also lead to enhanced BMP-2-induced bone formation. Since IL-17 is...

Descripción completa

Detalles Bibliográficos
Autores principales: Croes, M., Kruyt, M. C., Groen, W. M., van Dorenmalen, K. M. A., Dhert, W. J. A., Öner, F. C., Alblas, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940874/
https://www.ncbi.nlm.nih.gov/pubmed/29740080
http://dx.doi.org/10.1038/s41598-018-25564-9
_version_ 1783321175570513920
author Croes, M.
Kruyt, M. C.
Groen, W. M.
van Dorenmalen, K. M. A.
Dhert, W. J. A.
Öner, F. C.
Alblas, J.
author_facet Croes, M.
Kruyt, M. C.
Groen, W. M.
van Dorenmalen, K. M. A.
Dhert, W. J. A.
Öner, F. C.
Alblas, J.
author_sort Croes, M.
collection PubMed
description Interleukin 17 (IL-17) stimulates the osteogenic differentiation of progenitor cells in vitro through a synergy with bone morphogenetic protein (BMP)-2. This study investigates whether the diverse responses mediated by IL-17 in vivo also lead to enhanced BMP-2-induced bone formation. Since IL-17 is known to induce osteoclastogenesis, we studied the interactions between IL-17 and BMP-2 in ceramic scaffolds either or not carrying a coating with the bisphosphonate zoledronic acid (ZOL). Histological evaluation revealed that IL-17 alone did not induce any osteoclasts at day 10. On the other hand, BMP-2 clearly stimulated early tissue ingrowth and osteoclastogenesis. Both of these processes were blocked in presence of ZOL. IL-17 signaling restored early vascularized connective tissue formation and osteoclastogenesis induced by BMP-2 in ZOL-coated scaffolds. After 12 weeks, the bone volume induced by co-delivery of BMP-2 and IL-17 was doubled as compared to that induced by BMP-2 alone. We conclude that IL-17 has osteo-stimulatory effects through a synergy with bone-inductive BMP-2. Although local and single application of IL-17 does not mediate osteoclast formation, it could promote other processes involved in bone formation such as connective tissue ingrowth. The use of IL-17 may contribute to the development of improved bone graft substitutes.
format Online
Article
Text
id pubmed-5940874
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-59408742018-05-14 Interleukin 17 enhances bone morphogenetic protein-2-induced ectopic bone formation Croes, M. Kruyt, M. C. Groen, W. M. van Dorenmalen, K. M. A. Dhert, W. J. A. Öner, F. C. Alblas, J. Sci Rep Article Interleukin 17 (IL-17) stimulates the osteogenic differentiation of progenitor cells in vitro through a synergy with bone morphogenetic protein (BMP)-2. This study investigates whether the diverse responses mediated by IL-17 in vivo also lead to enhanced BMP-2-induced bone formation. Since IL-17 is known to induce osteoclastogenesis, we studied the interactions between IL-17 and BMP-2 in ceramic scaffolds either or not carrying a coating with the bisphosphonate zoledronic acid (ZOL). Histological evaluation revealed that IL-17 alone did not induce any osteoclasts at day 10. On the other hand, BMP-2 clearly stimulated early tissue ingrowth and osteoclastogenesis. Both of these processes were blocked in presence of ZOL. IL-17 signaling restored early vascularized connective tissue formation and osteoclastogenesis induced by BMP-2 in ZOL-coated scaffolds. After 12 weeks, the bone volume induced by co-delivery of BMP-2 and IL-17 was doubled as compared to that induced by BMP-2 alone. We conclude that IL-17 has osteo-stimulatory effects through a synergy with bone-inductive BMP-2. Although local and single application of IL-17 does not mediate osteoclast formation, it could promote other processes involved in bone formation such as connective tissue ingrowth. The use of IL-17 may contribute to the development of improved bone graft substitutes. Nature Publishing Group UK 2018-05-08 /pmc/articles/PMC5940874/ /pubmed/29740080 http://dx.doi.org/10.1038/s41598-018-25564-9 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Croes, M.
Kruyt, M. C.
Groen, W. M.
van Dorenmalen, K. M. A.
Dhert, W. J. A.
Öner, F. C.
Alblas, J.
Interleukin 17 enhances bone morphogenetic protein-2-induced ectopic bone formation
title Interleukin 17 enhances bone morphogenetic protein-2-induced ectopic bone formation
title_full Interleukin 17 enhances bone morphogenetic protein-2-induced ectopic bone formation
title_fullStr Interleukin 17 enhances bone morphogenetic protein-2-induced ectopic bone formation
title_full_unstemmed Interleukin 17 enhances bone morphogenetic protein-2-induced ectopic bone formation
title_short Interleukin 17 enhances bone morphogenetic protein-2-induced ectopic bone formation
title_sort interleukin 17 enhances bone morphogenetic protein-2-induced ectopic bone formation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940874/
https://www.ncbi.nlm.nih.gov/pubmed/29740080
http://dx.doi.org/10.1038/s41598-018-25564-9
work_keys_str_mv AT croesm interleukin17enhancesbonemorphogeneticprotein2inducedectopicboneformation
AT kruytmc interleukin17enhancesbonemorphogeneticprotein2inducedectopicboneformation
AT groenwm interleukin17enhancesbonemorphogeneticprotein2inducedectopicboneformation
AT vandorenmalenkma interleukin17enhancesbonemorphogeneticprotein2inducedectopicboneformation
AT dhertwja interleukin17enhancesbonemorphogeneticprotein2inducedectopicboneformation
AT onerfc interleukin17enhancesbonemorphogeneticprotein2inducedectopicboneformation
AT alblasj interleukin17enhancesbonemorphogeneticprotein2inducedectopicboneformation